HLOSF (Healios KK) Research & Development: $15.38 Mil (TTM As of Mar. 2026)


HLOSF Healios KK HLOSF
57 GF Score
Price $1.80
GF Value $0.42
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Research & Development?

Healios KK HLOSF 57 Research & Development is $15.38 Mil as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Healios KK's Research & Development for the three months ended in Mar. 2026 was $5.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $15.38 Mil.

Healios KK  (OTCPK:HLOSF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Healios KK Research & Development Related Terms

Healios KK Research & Development Historical Data

* Premium members only.

The historical data trend for Healios KK's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK Research & Development Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.50 28.23 16.00 12.74 12.98

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 4.04 3.16 3.15 5.03
HLOSF
57GF Score
Healios KK HLOSF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $15.38 Mil mean?
Healios KK (HLOSF) has a Research & Development of $15.38 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Healios KK and its competitors.
Is Healios KK's Research & Development too high?
Healios KK's current Research & Development is $15.38 Mil. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Research & Development compare to VRTX and REGN?
Healios KK's Research & Development of $15.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Healios KK and its competitors. Healios KK's current Research & Development is $15.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current Research & Development is $15.38 Mil. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Healios KK (HLOSF), the current Research & Development is $15.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (HLOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for HLOSF:

  • Research & Development: $15.38 Mil
  • GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges 4593:Japan6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score

Get the complete analysis for HLOSF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.42
GF Value